Display options
Cite
Córdova-Ramírez AC, Sánchez-Valledor LF, Colón-Otero G, et al. Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center. Rev Invest Clin. 2020;73(5)doi: 10.24875/RIC.20000381.
Córdova-Ramírez, A. C., Sánchez-Valledor, L. F., Colón-Otero, G., Rivera-Alvarez, M., Elías-de-la-Cruz, G. D., Murrieta-Alvarez, I., Cantero-Fortiz, Y., León-Peña, A., Olivares-Gazca, J. C., Ruiz-Delgado, G. J., & Ruiz-Argüelles, G. J. (2020). Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 73(5), . https://doi.org/10.24875/RIC.20000381
Córdova-Ramírez, Alejandra C, et al. "Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center." Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion vol. 73,5 (2020). doi: https://doi.org/10.24875/RIC.20000381
Córdova-Ramírez AC, Sánchez-Valledor LF, Colón-Otero G, Rivera-Alvarez M, Elías-de-la-Cruz GD, Murrieta-Alvarez I, Cantero-Fortiz Y, León-Peña A, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center. Rev Invest Clin. 2020 Oct 19;73(5). doi: 10.24875/RIC.20000381. Epub 2020 Oct 19. PMID: 33075042.
Copy Download .nbib Format: NLM
Share it on

Rev Invest Clin. 2020 Oct 19;73(5). doi: 10.24875/RIC.20000381. Epub 2020 Oct 19.

Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

Alejandra C Córdova-Ramírez, Luisa F Sánchez-Valledor, Gerardo Colón-Otero, Montserrat Rivera-Alvarez, Gilberto D Elías-de-la-Cruz, Iván Murrieta-Alvarez, Yahveth Cantero-Fortiz, Andrés León-Peña, Juan C Olivares-Gazca, Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles

Affiliations

  1. Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue.; Mexico.
  2. Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad de las Américas Puebla, Pue.; Mexico.
  3. Mayo Clinic, Jacksonville FL, USA.
  4. Centro de Hematología y Medicina Interna de Puebla, Pue.; Benemérita Universidad Autónoma de Puebla, Pue., Mexico.
  5. Centro de Hematología y Medicina Interna de Puebla, Pue.; Universidad Popular Autónoma del Estado de Puebla, Pue., 5aboratorios Ruiz, Puebla, Pue.; Mexico.

PMID: 33075042 DOI: 10.24875/RIC.20000381

Abstract

BACKGROUND: The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México.

OBJECTIVE AND METHODS: This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified.

RESULTS: There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006).

CONCLUSION: Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.

Publication Types